{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462258124
| IUPAC_name = (2''R'')-''N''-[(2''R'')-5-carbamimidamido-1-[(2''S'')-2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2''R'')-2-[(2''R'')-2-[(2''R'')-3-hydroxy-2-[(2''S'')-2-[(2''S'')-3-(1''H''-imidazol-4-yl)-2-<nowiki/>{[(2''R'')-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1''H''-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(naphthalen-2-yl)propanamido]-4-methylpentanamide
| image = Nafarelin.svg

<!--Clinical data-->
| tradename = Synarel
| Drugs.com = {{drugs.com|monograph|synarel}}
| MedlinePlus = a601082
| pregnancy_category = X
| legal_status = ℞-only
| routes_of_administration = [[Nasal spray]]

<!--Pharmacokinetic data-->
| elimination_half-life = 2.6 to 4 hours
| excretion = renal

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76932-56-4
| ATC_prefix = H01
| ATC_suffix = CA02
| PubChem = 25077649
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00666
| IUPHAR_ligand = 3902
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482014
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1X0094V6JV
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201309

<!--Chemical data-->
| C=66 | H=83 | N=17 | O=13 
| molecular_weight = 1321.6344 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RWHUEXWOYVBUCI-ITQXDASVSA-N
| smiles = CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@@H]8CCC(=O)N8
}}

'''Nafarelin''' is a [[gonadotropin-releasing hormone agonist]] (GnRH agonist). Its proposed mechanism of action is the desensitization of pituitary GnRH receptors leading to a decrease in gonadotropin release, and ovarian hormone serum concentrations similar to those achieved in postmenopausal women. it decreases pituitary secretion of the gonadotropins [[luteinizing hormone]] (LH) and [[follicle stimulating hormone]] (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as [[endometriosis]] or [[uterine fibroids]]), to treat central [[precocious puberty]], or to control ovarian stimulation in [[in vitro fertilisation]] (IVF).<ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=372–3|isbn=3-8047-1763-2}}</ref><ref>{{cite journal|pmid=8917899|year=1996|author1=Wuttke|first1=W|title=The neurochemistry of the GnRH pulse generator|journal=Acta neurobiologiae experimentalis|volume=56|issue=3|pages=707–13|last2=Jarry|first2=H|last3=Feleder|first3=C|last4=Moguilevsky|first4=J|last5=Leonhardt|first5=S|last6=Seong|first6=J. Y.|last7=Kim|first7=K|url=http://www.ane.pl/linkout.php?vol=56&no=3&fpp=707}}</ref>

Nafarelin [[acetate]] is marketed by Searle (now part of [[Pfizer]]) under the brand name '''Synarel'''. It is delivered via a nasal spray.<ref>[[Drugs.com]]: Synarel {{drugs.com|monograph|synarel}}</ref>

==Side effects==
Side effects of nafarelin are related to the low estrogen state. Side effects include hot flashes, vaginal dryness, headaches, mood changes, and decreased interest in sex. Some patients may experience acne, muscle pain, reduced breast size, and irritation of the tissue inside the nose. These side effects are reversible and should resolve after stopping the medication.<ref>DailyMed: [http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6 Synarel – nafarelin acetate spray]</ref>

==References==
{{Reflist|2}}


{{Gonadotropins and GnRH}}
{{Peptidergics}}

[[Category:GnRH agonists]]